An inactivated multicomponent Clostridium antigen API covering Braxy (Clostridium septicum), Struck (Clostridium perfringens type C), lamb dysentery (Clostridium perfringens type B), and enterotoxaemia (Clostridium perfringens type D) is specified where downstream manufacturers require a standardized toxoid/bacterin blend for parenteral veterinary immunoprophylaxis in sheep and goat flocks. Oral solid dosage forms such as tablets and capsules are not established downstream sectors for inactivated clostridial antigen in ruminant immunoprophylaxis; the API is accordingly specified for parenteral, solution, powder, and granule manufacturing routes. The API is supplied as a formalin-inactivated, detoxified culture concentrate or lyophilized powder; downstream formulation routes are constrained by the antigen’s aluminium adjuvant compatibility, thermal instability above 37°C, and sensitivity to pH excursions below 6.5. Contract manufacturing batches indicate that concentrated liquid API with dynamic viscosity above 25 cP at 20°C reduces transfer-line recovery by 6–10% if dead-leg volumes exceed 1.5 L and bend radii fall below 1.5 times pipe diameter.

What Makes Aluminium-Hydroxide-Adjuvanted Injectable Presentation the Default for Pre-Lambing Ewe Vaccination?

For pre-lambing ewe vaccination programs, the API is formulated into a multidose aqueous suspension where the terminal dose is 2.0 mL administered subcutaneously 4–6 weeks before lambing. Compliance obligations follow Ph. Eur. monograph 0062, Ph. Eur. 2.6.1 sterility, VICH GL2 stability, and 9 CFR Part 113 for inactivated bacterial products. The addition ratio is set by potency titration: the concentrated antigen is diluted between 1:1 and 1:4 with sterile phosphate-buffered saline pH 7.0–7.4, aluminium hydroxide gel is added at 1.0–2.0% w/v, and thiomersal is incorporated at 0.005–0.01% w/v only for multidose vials. Downstream production includes formalin inactivation at 0.3–0.5% w/v for 7 days at 37°C, neutralization with sodium metabisulfite, low-shear blending below 150 rpm to avoid aluminium hydroxide matrix disruption, and filling into 250 mL or 500 mL high-density polyethylene vials. High-shear agitation above 500 rpm is avoided because it disrupts the aluminium hydroxide gel matrix and produces visible sedimentation at 2–8°C after 30 days. Terminal finished product is an injectable suspension in multidose vials; freeze-thaw must be excluded because aluminium hydroxide gel aggregates irreversibly below 0°C.

Lyophilized API powder for downstream reconstitution into aqueous injectable fluids is specified in markets where cold-chain interruptions exceed 8 h at ambient temperatures above 30°C. This powder route is a stabilisation and logistics format for the inactivated antigen before terminal liquid compounding, not a final oral dosage form. The API is blended with mannitol/trehalose cryoprotectant at 1:0.5 to 1:2 w/w, filtered through a 0.45 µm polyethersulfone membrane prior to lyophilisation, and dried in stainless-steel trays with primary drying at -35°C to -30°C and chamber pressure 80–120 µbar for 36–48 h, followed by secondary drying at 20–25°C until the cake moisture is below 3.0% by Ph. Eur. 2.5.32 Karl Fischer titration. Compliance is governed by Ph. Eur. 0062, Ph. Eur. 2.6.1, and VICH GL2; the powder intermediate must be reconstituted under aseptic conditions because the final adjuvanted liquid cannot be sterile-filtered. The addition ratio of the lyophilized antigen complex in reconstituted fluid is 0.8–1.2 mg/mL before adjuvant addition; terminal finished product is a reconstituted injectable suspension in single-dose vials.

When Caprine Dairy Withdrawal Windows Constrain Preservative Selection, the Aqueous Solution Route is Reconfigured

In caprine dairy herds where milk-withholding perception and antimicrobial residue concerns constrain preservative use, the API is formulated into a preservative-free aqueous suspension with reduced aluminium hydroxide content. Compliance follows Ph. Eur. monograph 0062, EU Regulation 2019/6, and VICH GL2; sterility testing uses Ph. Eur. 2.6.1. Formulation addition is 1:2 dilution of the antigen concentrate with sterile water for injection, aluminium hydroxide gel at 0.5–1.0% w/v, and no thiomersal; benzyl alcohol and phenol are excluded because they produce visible protein flocculation at pH 6.5–7.0. Downstream production includes aseptic filling under ISO 14644-1:2015 Class 5 unidirectional airflow, final pH adjustment with 0.1 N NaOH to 6.8–7.0, and filling into 20 mL single-dose or 100 mL preservative-free multidose vials with a recommended discard period of 10 h after first broaching. Terminal finished product is an injectable suspension for subcutaneous administration at 1.0 mL per goat; do not freeze or store above 8°C.

At concentrate-based lamb finishing units where dietary starch exceeds 60% of dry matter and ruminal pH remains below 5.8 for more than 6 h/day, the epsilon toxoid fraction is formulated to a minimum potency of 5 IU per 2.0 mL dose. The combined antigen is diluted from stock at 1:1.5 into sterile diluent, aluminium hydroxide gel is added at 1.5% w/v, and thiomersal is maintained at 0.01% w/v in multidose packs. Downstream processing includes cooling the antigen to 4°C before adjuvant addition to reduce adsorption enthalpy, blending with magnetic-coupled impellers at 100–200 rpm for 90 min, and filling into 250 mL flexible polypropylene packs using peristaltic pumps with 0.45 µm vent filters. Compliance obligations are Ph. Eur. 0062, 9 CFR Part 113, and VICH GL2; potency testing is by mouse challenge or validated ELISA according to the manufacturer’s approved method. Terminal finished product is an adjuvanted injectable suspension for lambs from 8 weeks of age, with a second dose after 4–6 weeks.

Multivalent Blending Interface for Mixed Ovine-Caprine Herd Protection

Blending of the four-component API into wider clostridial combinations, such as 7-in-1 or 8-in-1 ovine vaccines that also include Clostridium novyi, Clostridium tetani, and Clostridium chauvoei fractions, requires compatibility monitoring for residual proteolytic activity from C. septicum alpha toxoid. The combined API is added at 40–70% v/v of the total antigen volume, with each additional toxoid adjusted from 5–15% v/v according to potency titre. Compliance is governed by Ph. Eur. 0062, 9 CFR Part 113, and EU Regulation 2019/6; final product sterility follows Ph. Eur. 2.6.1. Downstream production uses 500 L stainless-steel vessels with nitrogen overlay, blending at 100–200 rpm for 120 min at 2–8°C, and residual formaldehyde is controlled at less than 0.5 g/L. Incompatibility is documented with amine-based buffering additives, which accelerate epsilon toxoid crosslinking and reduce potency; phosphate-buffered saline is used instead. Terminal finished product is a liquid multivalent injectable vaccine for sheep and goats, supplied in 50 mL, 250 mL, and 500 mL presentations.

Granulated premix intermediates of the inactivated antigen are produced by spray-coating the concentrated liquid API onto a pharmaceutical-grade mannitol and trehalose carrier at 35–40°C inlet air temperature, yielding granules with bulk density 0.45–0.60 g/cm³ and residual moisture below 3.0%. Contract formulation sites reconstitute the premix at 1:1.2 solid-to-buffer ratio, add aluminium hydroxide gel at 1.5% w/v, and re-verify pH, sterility, and identity prior to final filling. Compliance under ISO 14644-1:2015 Class 7 background and Class 5 local aseptic zones includes Ph. Eur. 2.6.1 and 9 CFR Part 113. The terminal finished product is a multidose injectable suspension for veterinary clinics and flock health programs; frozen storage is excluded because aluminium hydroxide gel precipitation after thawing cannot be fully redispersed.